Renata launches Fludrocortisone tablets in UK
Renata PLC has launched Fludrocortisone 0.1mg tablets in the United Kingdom, strengthening its product portfolio in a key international market.
Fludrocortisone is indicated for partial replacement therapy in primary adrenocortical insufficiency (Addison's disease) and for the treatment of salt-losing adrenogenital syndrome. The product is supplied from Renata's UK MHRA-approved potent product facility.
Renata's Fludrocortisone tablets offer a notable advantage in storage conditions, remaining stable at temperatures below 25°C, unlike the innovator product, which requires refrigeration between 2 °C and 8°C. This innovation provides practical benefits for patients and healthcare providers, while also enhancing the company's competitive position.
Keep updated, follow The Business Standard's Google news channel
The launch underscores Renata's expertise in developing potent pharmaceutical products and reflects its strategic commitment to expanding its presence in the UK and other highly regulated markets.
